RxDoctor Payments DataLook up a doctor →

Simon Fishman, MD

Neurology · Alexandria, VANPI 1578654968

Payments from drug & device makers

$1,603,062in general payments, 2019–2025

Across 1,852 payments — averaging $865.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$876K
  • Novartis$184K
  • Eli Lilly$136K
  • Novo Nordisk AS$131K
  • Biogen$126K
  • Genentech, Inc.$86K
  • plus $63K from 54 others
$24,529in research payments, 2019–2025

Across 11 payments — averaging $2229.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$23K
  • AbbVie$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)458$876,436
Novartis174$183,677
Eli Lilly3$136,074
Novo Nordisk AS43$131,379
Biogen262$126,041
Genentech, Inc.18$86,055
EMD Serono, Inc.124$30,513
Teva Pharmaceuticals USA, Inc.60$15,616
Amgen(2 entities)71$1,726
Lilly USA, LLC67$1,504
Lundbeck LLC44$1,109
Medtronic11$957
Bristol Myers Squibb56$895
Genentech USA, Inc.70$832
TG Therapeutics, Inc.8$670
Pfizer25$608
UCB, Inc.30$572
Axsome Therapeutics, Inc.11$556
AstraZeneca(2 entities)18$551
MDD US Operations, LLC11$533
Neurelis, Inc.28$515
Argenx US, Inc.21$449
Eisai Inc.29$438
Biohaven Pharmaceutical Holding Company Ltd.9$399
Biohaven Pharmaceuticals, Inc.13$392
Harmony Biosciences LLC16$385
Merz Pharmaceuticals, LLC7$296
E.r. Squibb & Sons, L.L.C.8$269
Neurocrine Biosciences, Inc.8$268
Acorda Therapeutics, Inc12$220
Averitas Pharma Inc.5$206
Adamas Pharmaceuticals, Inc.10$183
Avanir Pharmaceuticals, Inc.12$180
Sanofi7$154
Grifols USA, LLC7$144
GE HealthCare5$141
Jazz Pharmaceuticals Inc.5$132
Vanda Pharmaceuticals Inc.5$129
Inspire Medical Systems, Inc.2$120
Amneal Pharmaceuticals LLC6$116
Sunovion Pharmaceuticals Inc.1$116
Supernus Pharmaceuticals, Inc.5$112
Insightec,inc1$110
Upsher-smith Laboratories LLC5$105
Kyowa Kirin, Inc.5$93
Livanova USA, Inc.5$92
Merz North America, Inc.2$86
Revance Therapeutics, Inc.2$78
Otsuka America Pharmaceutical, Inc.4$67
Sandoz2$53
Johnson & Johnson3$52
CSL Behring2$51
Takeda Pharmaceuticals U.S.A., Inc.2$50
Corium, LLC5$47
Tanabe Pharma America, Inc.2$41
Currax Pharmaceuticals LLC3$41
Catalyst Pharmaceuticals, Inc.2$36
Assertio Therapeutics, Inc.2$36
Vertical Pharmaceuticals, LLC2$36
Boston Scientific1$32

How this compares

$1,603,062 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia →

Medicare billing

Part B allowed, 2024
$917,370
Medicare patients
1,386
Services billed
43,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Alexandria

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →